What Санвал Treats: Main Uses and Benefits

The primary role of Санвал (Zolpidem) is to provide supportive, short-term relief for the symptoms of insomnia, a condition that interferes with daily functioning. The medication is commonly used to help manage symptomatic clusters related to sleep initiation and maintenance difficulties.

Targeted Symptom Relief

This medication is generally applied in situations involving certain distressing symptoms, primarily addressing the inability to fall asleep quickly (sleep latency) and unwanted, repeated nocturnal awakenings that reduce the total time spent sleeping. It is relevant in contexts marked by increased discomfort or tension, such as acute stress or temporary environmental shifts, which can trigger severe sleep difficulties. It may be part of symptomatic management when sleeplessness leads to functional strain or distress.

“The therapeutic support provided aims to ease the overall burden of sleep deprivation and assists with maintaining functional stability.”

Clinical Application and Benefit

Санвал is commonly used across conditions presenting with acute episodes of insomnia, particularly when the severity of symptoms becomes temporarily overwhelming. The relevant patient-oriented benefit is symptomatic relief that contributes to improved rest and an increase in total sleep duration. This assistance may help patients cope more steadily with difficult episodes and supports the reduction of time spent awake during the night.

Quick Fact: Relief for Insomnia Symptoms
Primary Symptom Focus	Difficulty falling asleep (Sleep Latency)
Secondary Symptom Focus	Difficulty staying asleep (Nocturnal Awakenings)
Typical Use Context	Short-term symptomatic assistance

Eligibility and Contraindications

The eligibility to use Санвал (Zolpidem) is strictly defined by regulatory documents based on age, organ function, and specific medical conditions. Use is authorized for adults 18 years and older who do not have any contraindications.

Populations Who Must Not Use the Medicine

The medicine is strictly contraindicated in several groups, including patients with severe hepatic insufficiency (liver problems), sleep apnoea syndrome, myasthenia gravis, or severe respiratory insufficiency. Use is also prohibited for individuals with a known hypersensitivity to zolpidem or who have a history of complex sleep behaviors (e.g., sleep-driving) after prior use.

Restricted and Conditional Use

The drug is not recommended for the pediatric population (under 18) because safety and effectiveness have not been established. Elderly patients (65 and older) are permitted use, but regulatory documents recommend a lower initial dose due to increased sensitivity and risk of adverse effects. Patients with mild to moderate hepatic impairment or chronic respiratory insufficiency also require cautious, lower-dose use. Use during pregnancy is generally not recommended. During lactation, zolpidem is excreted in human milk, leading to official recommendations to discard breast milk for a period after administration.

Interactions with other medicines and products

Official regulatory information for Санвал (Zolpidem) details specific interactions that may alter its effects or lead to additive side effects. These documented interactions primarily fall into two categories: Pharmacodynamic (additive effects) and Pharmacokinetic (metabolic effects).

Interaction Type	Documented Interacting Substances	Official Regulatory Description
Pharmacodynamic	Alcohol; Opioids; CNS Depressants (e.g., Anxiolytics, certain Antidepressants)	Co-administration may cause additive CNS-depressant effects, increasing risk of sedation, impaired psychomotor performance, and respiratory depression (FDA/EMA).
Pharmacokinetic	Rifampin (CYP3A4 Inducer); Ketoconazole (CYP3A4 Inhibitor); St. John’s Wort	CYP3A4 inducers (like Rifampin) decrease Zolpidem exposure, potentially reducing its effect. CYP3A4 inhibitors (like Ketoconazole) increase Zolpidem exposure and clinical effects.

Co-administration with Alcohol is explicitly advised against in official labeling due to the risk of additive impairment. Consumption of the oral tablet with or immediately after a meal is discouraged, as food can delay the absorption rate, potentially slowing the onset of effect. Use is avoided in patients with severe hepatic impairment due to reduced drug clearance, which increases the risk of heightened exposure.

How Санвал Works

---

Targeted Modulation of the Central Inhibitory System

The active ingredient, Zolpidem, functions as a Positive Allosteric Modulator (PAM) of the GABA A receptor, the principal inhibitory system in the brain. This modulation is highly selective, primarily targeting the receptor subtypes containing the alpha1 subunit. This specific interaction enhances the effect of the endogenous neurotransmitter GABA, initiating the required cascade for Central Nervous System (CNS) suppression.

---

️ Ion Channel Activity and Neuronal Hyperpolarization

The allosteric binding stabilizes the GABA A receptor, leading to a prolonged opening of its central ion channel when GABA binds. This event facilitates a rapid and sustained influx of negatively charged Chloride ions ( Cl^-) into the nerve cell. The cellular consequence of this increased negative charge is neuronal hyperpolarization, which makes the cell resistant to excitatory signals, resulting in reduced excitability in neural circuits associated with arousal.

---

Systemic Effect: Modulation of Arousal Networks

The resulting widespread, targeted enhancement of the GABAergic inhibitory drive leads to functional CNS depression, specifically dampening activity in the cortical and subcortical arousal centers. This physiological consequence includes a facilitation of the transition of the central nervous system into a sleeping state and is associated with the maintenance of a sleeping state by modulating the signaling patterns that promote arousal during sleep.

Administration and Dosing Guidelines

Санвал (Zolpidem) is administered via the oral route as a single dose once per night, taken immediately before going to bed. The official administration guidelines are defined by strict limitations on frequency, timing, and total course duration.

Standard Dosing Regimens

The approved dosage dictates that the lowest effective dose must be used. For immediate-release (IR) tablets, the maximum daily dose is 10 mg. The initial recommended dose for adult women is 5 mg (IR), while adult men may start at 5 mg or 10 mg. The medicine must not be re-administered during the same night.

Population-Specific Use

Dose reductions are specified for certain populations to mitigate systemic exposure. Both older adults (geriatric patients) and patients with hepatic impairment should initiate treatment at the reduced dose of 5 mg (IR) or 6.25 mg for extended-release forms. Use is not recommended in individuals under 18 years of age due to lack of established data.

Contextual Use Requirements

The usage protocol establishes critical requirements for proper intake:

• Sleep Window: The tablet must only be taken when the patient has at least 7 to 8 hours available for sleep.
• Food Intake: Taking the dose with or immediately after a meal may slow the onset of the medicine and should be avoided.
• Formulation Handling: Extended-release tablets must be swallowed whole and are not to be crushed, divided, or chewed.

Treatment Duration

The official instruction is that treatment should be for the shortest possible duration. The total course of administration is generally not to exceed four weeks, which includes any necessary period for dose reduction.

Research evidence / Overview of studies for Санвал

Evidence for Short-term Treatment of Insomnia Disorder

Randomized Controlled Trials (RCTs) are a key type of study used to explore effects. These trials compare the outcomes of patients receiving the medicine against those receiving an inactive comparison pill (placebo). Subsequent Meta-Analyses have been applied to combine the data from multiple short-term RCTs, providing a broader overview of observed patterns.

Research has primarily examined outcomes related to systemic or functional imbalance associated with insomnia. These include outcomes describing episodic or acute changes in metrics such as the time taken to fall asleep. Studies monitored physiological strain or stress relevant in evidence describing how symptoms are measured.

Evaluation of Study Outcomes: Sleep Initiation and Maintenance

In the studies, researchers specifically monitored outcomes capturing phases of heightened symptom activity, particularly the difficulty of initiating sleep. Studies monitored the time required to achieve sleep onset as a primary outcome. Additionally, studies explored outcomes related to the number of nocturnal awakenings and the total time patients remained awake after initially falling asleep, known as Wake After Sleep Onset (WASO).

Research describes patterns observed in the studies related to sleep initiation. Studies described patterns observed in the measured time taken to fall asleep. However, evidence related to changes in the maintenance of sleep, meaning the number of nocturnal awakenings, was observed in some studies but findings were mixed across the broader evidence landscape.

Duration of Evidence: Long-term Studies and Follow-up Data

The research conducted on Zolpidem was primarily designed to examine temporary physiological imbalance and assess short-term symptom changes, with most core RCTs having follow-up durations that were limited, usually lasting no more than 16 weeks. Research provides insight into short-term changes. Long-term outcomes regarding extended time intervals are not well characterized, particularly for patients whose condition is characterized by chronic or functional limitations. Consequently, evidence is limited regarding outcomes observed continuously for periods extending beyond six months.

Common questions about Санвал (FAQ)

---

Q: If I wake up in the middle of the night, can I take another dose?

Official administration guidelines state that Zolpidem should be taken as a single dose once per night. Regulatory labeling states that the medicine should not be re-administered during the same night. Taking more than the recommended single dose is associated with an increased risk of next-day impairment, which may affect activities requiring full alertness.

---

Q: Will I get addicted if I use this medicine for a long time?

Regulatory documents indicate that the risk of developing dependence and tolerance is noted to increase with prolonged use of the medicine. Due to this safety concern, official prescribing information recommends that treatment be for the shortest possible duration, generally not exceeding four weeks.

---

Q: Does Sanval help me stay asleep throughout the night?

Official information indicates that Zolpidem is used for treating insomnia, which includes addressing difficulties with sleep maintenance (staying asleep). Some specific formulations, such as the extended-release type, are designed to assist with sleep maintenance.

---

Q: What should I do if I miss a dose of Sanval?

According to official resources, if a dose is missed, the general guidance is to skip the missed dose entirely. The dose should only be taken when an individual can ensure they have a full 7 to 8 hours remaining for sleep, as stated in the administration requirements.

---

Q: How do I know if the tablet is immediate-release (IR) or extended-release (ER)?

The immediate-release and extended-release tablets are distinguished by their physical characteristics. Official labeling specifies that different forms of the tablet are manufactured with unique shapes, colors, or imprints (markings) on the tablet itself. This specific identification information is detailed in the product labeling.

---

Q: How long does it take for Sanval to start working?

Zolpidem is described as being rapidly absorbed by the body. This rapid absorption contributes to a short onset of action, which is relevant to its intended use for sleep initiation. However, taking the medicine with or immediately after a full meal may delay the onset of the effect.

---

Q: Is Sanval (Zolpidem) a Benzodiazepine?

No, Sanval (Zolpidem) is not classified as a Benzodiazepine. Official product information describes it as a non-benzodiazepine sedative-hypnotic agent, often referred to as a 'Z-drug.'

Official Storage and Disposal Requirements

Storage and disposal requirements for Sanval (Zolpidem) are defined by government regulatory documents to ensure product stability and safety. This information is non-advisory and label-based.

Storage Conditions:

The product must be stored under controlled room temperature conditions, typically not exceeding 25 C to 30 C. The medicine should be kept in its original packaging to protect it from exposure to light and moisture. To maintain safety, it is a mandatory regulatory requirement that the product be kept out of the sight and reach of children.

Disposal Instructions:

Official labeling generally states that no special requirements are necessary for the disposal of unused or expired Sanval. Disposal should follow established local regulatory procedures for pharmaceutical waste. Care must be taken to avoid release of the product into the environment, such as disposing of it in household trash or flushing it down a toilet.